References
- Garnett C, Apperley JF, Pavlů J. Treatment and management of graft-versus-host disease: improving response and survival. Ther Adv Hematol. 2013;4:366–378.
- Levine JE, Braun TM, Harris AC, et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. The Lancet Haematology. 2015;2:e21–e29.
- Berger M, Biasin E, Saglio F, et al. Innovative approaches to treat steroid-resistant or steroid refractory GVHD. Bone Marrow Transplant. 2008;42:S101–S105.
- Deeg HJ. How I treat refractory acute GVHD. Blood 2007;109:4119–4126.
- Markey KA, MacDonald KP, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood 2014;124:354–362.
- Actemra (tocilizumab) [prescribing information]. San Francisco, CA: Genetech Inc; 2014.
- Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant. 2011;17:1862–1868.
- Roddy JV, Haverkos BM, McBride A, et al. Tocilizumab for steroid refractory acute graft-versus-host disease. Leuk Lymphoma. 2016;57:81–85.
- Przepiorka D, Martin P, Klingemann HG, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825–828.
- Chen X, Das R, Komorowski R, et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 2009;114:891–900.
- Ganetsky A, Hexner EO, Loren A, et al. Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplant 2018; [cited 2018 May 24].
- Kennedy GA, Varelias A, Vuckovic S, et al. Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial. The Lancet Oncology. 2014;15:1451–1459.